Across TCGA pan-cancer cohorts, IGHV4-39 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated IGHV4-39 data layer compared with 26 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IGHV4-39 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IGHV4-39 expression acts as an unfavorable survival marker.
LUAD are the cancer types where IGHV4-39 mass-spec protein most reproducibly stratifies survival.